HUTCHMED

London: Wednesday, 24 April 2013: Nutrition Science Partners, a 50/50 joint venture between Chi-Med and Nestlé Health Science, today announces that the first patient has been enrolled and has begun treatment in the first global Phase III study of HM

Initiation of Phase I clinical trial of novel Syk Inhibitor HMPL - 523 for autoimmune diseases

Initiation of fruquintinib Phase II study in non-small cell lung cancer

Chi-Med and Shanghai Traditional Chinese Medicine expand commercial cooperation

Initiation of AZD6094 (HMPL-504/volitinib) Global Phase II Study in Papillary Renal Cell Carcinoma

Phase I clinical data for selective VEGFR, c-Met and VEGFR/FGFR inhibitors to be presented at the 2014 ASCO Annual Meeting

Chi-Med and Sinopharm complete regulatory approval for the establishment of new China drug distribution and marketing Joint Venture

Presentations of volitinib and epitinib data at the 2014 AACR Annual Meeting

Initiation of fruquintinib Phase II study in colorectal cancer

Final Results for the year ended 31 December 2013

Chi-Med and Sinopharm form China drug distribution and marketing joint venture

Chi-Med's Pharmaceutical R&D Business - Analyst & Investor Briefing

Candidate Nomination of Novel Small-Molecule Therapy in Inflammation Triggers Milestone Payment From Janssen Pharmaceuticals, Inc.

Cancer Therapy Collaboration with Lilly

Analyst briefing on Chi-Med's pharmaceutical R&D business on 9 October 2013

Interim Results for the Six Months Ended 30 June 2013

Nutrition Science Partners announces initiation of NATRUL-4, the maintenance study of the global Phase III trial for HMPL-004

Initiation of Volitinib China Phase I study triggers US$5 million milestone payment

Nutrition Science Partners announces initiation and treatment of the first Ulcerative Colitis patient in the global NATRUL Phase III trial for the novel botanical oral drug HMPL-004

Nestlé Health Science and Chi-Med complete regulatory approvals for the establishment of Nutrition Science Partners Joint Venture

Presentations of Fruquintinib Phase I Clinical Data and Volitinib Preclinical Data at the 2013 AACR Annual Meeting

Final Results for the year ended 31 December 2012

Chi-Med and Nestlé Health Science establish Joint Venture

Hutchison MediPharma Limited initiates Phase I clinical study with its novel EGFR inhibitor Theliatinib

Interim Results for the Six Months Ended 30 June 2012

Hutchison MediPharma Limited Announces Presentations of Sulfatinib and Fruquintinib Clinical Data at the 2012 ASCO Annual Meeting

Final Results for the year ended 31 December 2011. Strong growth. Positive outlook

Hutchison MediPharma Limited initiates Phase I clinical study of its novel c-Met inhibitor Volitinib

AstraZeneca and Chi-Med enter into global collaboration to co-develop and commercialise novel cancer therapy

Hutchison MediPharma Limited initiates Phase I clinical study for its novel EGFR inhibitor Epitinib

Interim Results for the Six Months Ended 30 June 2011

China Healthcare Division expands OTC drug distribution and marketing operations

Final Results for the year ended 31 December 2010 Strong performance across all divisions.

Fruquintinib receives SFDA IND approval Starts Phase I Clinical Trial for the treatment of cancer

Hutchison MediPharma Receives Further Strategic Investment to Advance Its Pipeline

China Healthcare Division Chi-Med increases indirect ownership of its Hutchison Baiyunshan joint venture

Hutchison MediPharma Receives Strategic Investment to Advance Its Pipeline

Hutchison Hain Organic launch EARTH'S BEST® and ZHI LING TONG Co-branded Infant formula in China

Interim Results for the Six Months Ended 30 June 2010 Strong results. Continued momentum. Positive outlook.

Hutchison MediPharma Limited Receives SFDA IND Approval and Begins Phase I Clinical Trial of Sulfatinib for the Treatment of Cancer

Seven-year extension of IP protection for Chi-Med's main prescription drug

Final Results for the year ended 31 December 2009

Three more of Chi-Med's China Healthcare Division drugs added to latest China's National Medicines Catalogue

Successful Global Phase IIb Ulcerative Colitis Trial for HMPL-004: All Primary and Secondary Endpoints Achieved Hutchison MediPharma Proceeding with Development and Partnership Plans

Hutchison MediPharma Limited Initiates Phase I Clinical Trial of HMPL-011, Its Novel Single Chemical Drug Candidate for the Treatment of Auto-immune Diseases

Chi-Med increases ownership of its Hutchison Healthcare joint venture to 100%

Newly Published China National Essential Medicines List Reference Prices No Overall Negative Impact on Chi-Med Prices

Chi-Med announces joint venture with The Hain Celestial Group to develop natural and organic consumer products in Asia

Chi-Med's Main Drugs Included in the New National Essential Medicines List

Interim Results for the Six Months Ended 30 June 2009

Patient Enrolment Completed Ahead of Schedule for the Global Phase IIb Ulcerative Colitis Trial of HMPL-004